Key Considerations

• New product development cycle mirrors new drug development timeline

• Patent expirations

• New product pipelines thin and early stage

  • Pricing pressure on supplier base

• Strong corporate governance

• Management incentives strongly tied to creation of shareholder value

Previous slide

Next slide

Back to first slide

View graphic version